Hrt Financial LP Jounce Therapeutics, Inc. Transaction History

Hrt Financial LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$2.8 - $7.67 $56,028 - $153,476	20,010 New	20,010 $60,000
Q3 2021 Nov 15, 2021	SELL	$5.04 - $8.73 $112,165 - $194,286	-22,255 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$6.58 - $10.66 $129,698 - $210,119	-19,711 Reduced 46.97%	22,255 $151,000
Q1 2021 May 17, 2021	BUY	$6.73 - $13.87 $282,431 - $582,068	41,966 New	41,966 $430,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.